- Conditions
- Recurrent Medulloblastoma, Recurrent Ependymoma
- Interventions
- Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • New York, New York • Cincinnati, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 68
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Relapsed Multiple Myeloma
- Interventions
- Carfilzomib, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 11
- States / cities
- Long Beach, California • Los Angeles, California • San Francisco, California + 8 more
- Conditions
- Newly Diagnosed Multiple Myeloma
- Interventions
- Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Ixazomib
- Drug
- Lead sponsor
- Larysa Sanchez
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Melphalan, Prednisone, Carfilzomib
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 16
- States / cities
- Southington, Connecticut • Jacksonville, Florida • Orlando, Florida + 12 more
- Conditions
- Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
- Interventions
- Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate (Intrathecal Administration), Methotrexate (Intravenous Administration), Dexamethasone, Doxorubicin, Thioguanine, Methotrexate Oral Product
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Dallas, Texas
- Conditions
- Shoulder Pain, Injury of Shoulder Region, Disorder of Shoulder, Disorder of Rotator Cuff, Disorder of Tendon of Biceps
- Interventions
- Dexamethasone, Bupivacaine
- Drug
- Lead sponsor
- Lifespan
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Newport, Rhode Island
- Conditions
- Multiple Myeloma
- Interventions
- Part 1 (Dose Escalation): Daratumumab, Part 2 (Dose Expansion): Daratumumab, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- AL Amyloidosis
- Interventions
- Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg, Dexamethasone Oral, 10 mg, Dexamethasone Oral, 20 mg, Daratumumab Injection, Bendamustine, Pomalidomide, Ixazomib, Venetoclax MTD with Dexamethasone
- Drug · Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • St Louis, Missouri + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Cyclophosphamide, Dexamethasone
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 9
- States / cities
- Encinitas, California • West Hollywood, California • Whittier, California + 6 more
- Conditions
- Macular Edema, Uveitis
- Interventions
- Periocular triamcinolone 40 mg, Intravitreal triamcinolone 4 mg, Dexamethasone intravitreal implant
- Drug
- Lead sponsor
- JHSPH Center for Clinical Trials
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 23
- States / cities
- Los Angeles, California • San Francisco, California • Miami, Florida + 17 more
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Cyclophosphamide, Dexamethasone, Granulocyte Colony-Stimulating Factor
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Multiple Myeloma in Relapse
- Interventions
- Selinexor, Pomalidomide, Daratumumab, Carfilzomib, Dexamethasone
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Ureteral Stent-Related Symptom
- Interventions
- Dexamethasone Sodium Phosphate Injection 20 mg, Dexamethasone Sodium Phosphate Injection 4mg
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Interventions
- Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate
- Drug
- Lead sponsor
- Retina Vitreous Associates of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab Injection, Dexamethasone Oral, Lenalidomide Pill, Bortezomib Injection
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Deviated Nasal Septum
- Interventions
- Ropivacaine, Dexamethasone, Placebo
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Post-operative Pain, Opioid Use, Cleft Palate
- Interventions
- Quadratus lumborum block, Local anesthetic infiltration
- Procedure
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Venetoclax, Bortezomib, Dexamethasone, Placebo for venetoclax
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Durham, North Carolina • Canton, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 9
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Fort Collins, Colorado + 6 more
- Conditions
- Total Knee Replacement, Knee Arthroplasty
- Interventions
- Bupivacaine-Liposomal Bupivacaine, Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- Malignant Neoplasm
- Interventions
- Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate, Rescue Medications, Fulvestrant, Exemestane, Megestrol acetate/Medroxyprogesterone acetate, Tamoxifen, Letrozole
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- Anchorage, Alaska • Miami Beach, Florida • Shreveport, Louisiana + 6 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- RO7283420, Tocilizumab, Dasatinib, Dexamethasone, Paracetamol/acetaminophen, Diphenhydramine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Sacramento, California • Houston, Texas
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Bortezomib, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Vincristine, Triple IT Therapy
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 20
- States / cities
- Duarte, California • Long Beach, California • Los Angeles, California + 16 more
- Conditions
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
- Interventions
- Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 11 more